Comparative Pharmacology
Head-to-head clinical analysis: ATMEKSI versus STENDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATMEKSI versus STENDRA.
ATMEKSI vs STENDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation in corpus cavernosum, leading to smooth muscle relaxation and increased penile blood flow.
1.5 mg/kg IV every 4 weeks
50 mg orally once daily as needed, 1 hour before sexual activity. Maximum dose 100 mg. Maximum frequency once daily.
None Documented
None Documented
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Terminal elimination half-life is approximately 4 hours in healthy subjects; may be prolonged in hepatic impairment (Child-Pugh B: up to 6 hours) or with concomitant CYP3A4 inhibitors.
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Fecal (approximately 63%) and renal (approximately 21%) as metabolites; less than 2% excreted unchanged in urine.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor